OINDPnews


H&T Presspart Low GWP Banner

News

Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray

Perrigo said that Adapt Pharma and Opiant Pharmaceuticals have initiated patent litigation in the United States District Court for the District of New Jersey in regards to Perrigo's recently filed ANDA for a generic version of Narcan naloxone nasal spray for the treatment of opioid overdose. Adapt Pharma licensed naloxone nasal spray from Opiant (then called … [Read more...] about Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray

Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor

Galecto Biotech announced that it raised €79 million in a series C financing round that will be used to fund a Phase 2/3 study of its TD139, an inhaled galectin-3 inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). New investors included Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Maverick Ventures, Seventure Partners, and … [Read more...] about Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor

Phillips-Medisize CEO Matt Jennings appointed to Dance Biopharm board of directors

Dance Biopharm has announced the appointment of Phillips-Medisize President and CEO Matt Jennings to its board of directors. Phillips-Medisize is developing a connected version of Dance’s insulin soft mist inhaler device. Jennings joined Phillips-Medisize as Chairman, CEO and President in 2011; his prior experience includes 5 years as President of Teleflex and 2 … [Read more...] about Phillips-Medisize CEO Matt Jennings appointed to Dance Biopharm board of directors

Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil

Milestone Pharmaceuticals said that it has completed an $80 million financing round led by RTW Investments, a new investor. Proceeds will be used for Phase 3 development of its intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT), which recently got underway, for certain commercial activities prior to an anticipated launch of the … [Read more...] about Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil

Acerus Pharmaceuticals initiates Phase 1 study of intranasal cannabis oil

Acerus Pharmaceuticals has announced the initiation of a Phase 1 clinical trial of an intranasal formulation of cannabis oil, which the company said is "a preliminary step in a broader strategy focused on identifying additional applications for Acerus’ proprietary nasal delivery technology, including for prescription medical marijuana." The company has developed … [Read more...] about Acerus Pharmaceuticals initiates Phase 1 study of intranasal cannabis oil

Positive Phase 2b results for both Oyster Point nasal sprays for dry eye disease

Oyster Point Pharma has announced that separate Phase 2b studies of its OC-01 and OC-02 nicotine acetylcholine receptor (nAChR) agonist nasal sprays for the treatment of dry eye disease both showed improvement in dry eye symptoms for patients using the nasal sprays. Positive results for a previous Phase 2b trial of OC-2 were announced in July 2018. Oyster Point … [Read more...] about Positive Phase 2b results for both Oyster Point nasal sprays for dry eye disease

Biohaven Pharmaceutical initiates Phase 1 study of intranasal migraine candidate

Biohaven Pharmaceutical said that it has initiated a Phase 1 trial of its BHV-3500, an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist delivered via the Aptar Pharma Unit Dose System after the FDA approved its IND. The trial will evaluate various doses of BHV-3500, which the company is developing for the treatment of migraine.The company … [Read more...] about Biohaven Pharmaceutical initiates Phase 1 study of intranasal migraine candidate